Spero Therapeutics Files 8-K

Ticker: SPRO · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1701108

Spero Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpero Therapeutics, Inc. (SPRO)
Form Type8-K
Filed DateOct 29, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.001, $76.3 million, $1.1 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-condition

TL;DR

Spero Therapeutics filed an 8-K on 10/29/24 detailing its financial condition and corporate info.

AI Summary

Spero Therapeutics, Inc. filed an 8-K on October 29, 2024, reporting on its financial condition and other events. The filing indicates the company's principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139. The company was incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides an update on Spero Therapeutics' corporate and financial status, which is crucial for investors to understand the company's operational context.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.

Key Numbers

  • 001-38266 — Commission File Number (Identifies the company's SEC filing record)
  • 46-4590683 — I.R.S. Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Spero Therapeutics, Inc. (company) — Registrant
  • October 29, 2024 (date) — Date of earliest event reported
  • 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139 (location) — Principal executive offices
  • Delaware (jurisdiction) — State of incorporation

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on the company's Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on October 29, 2024.

Where are Spero Therapeutics, Inc.'s principal executive offices located?

Spero Therapeutics, Inc.'s principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139.

In which state was Spero Therapeutics, Inc. incorporated?

Spero Therapeutics, Inc. was incorporated in Delaware.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Stats: 1,467 words · 6 min read · ~5 pages · Grade level 13.8 · Accepted 2024-10-29 17:01:05

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
  • $76.3 million — h and cash equivalents of approximately $76.3 million as of September 30, 2024. A copy of the
  • $1.1 million — restructuring charges of approximately $1.1 million in cash expenditures in connection with

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits Exhibit Number Description 99.1 Press Release, dated October 29, 2024. 99.2 Corporate Investor Presentation of Spero Therapeutics, Inc. as of October 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 29, 2024 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer and Chief Business Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.